The country’s Standing Vaccination Commission recommended on Tuesday that AstraZeneca’s Vaxzevria only be given to men and women over the age of 60, or in exceptional cases. The decision was made due to “available, albeit limited, evidence” concerning the drug’s safety.
The commission announced its recommendation hours after the city of Berlin introduced an identical policy. Earlier, two state-owned clinics in the city halted AstraZeneca shots for women under 55 years of age. Munich followed suit with its own rule banning the shot for people under 60.
Health Minister Jens Spahn was scheduled to speak with regional counterparts about the AstraZeneca drug later on Tuesday, a ministry spokesperson announced. Germany had suspended emergency use of the AstraZeneca shot earlier this month, but then lifted the temporary ban after EU regulators deemed it to be safe.
The latest restrictions placed on the drug come after Germany’s vaccine regulator, the Paul Ehrlich Institute, disclosed that as of March 29, the country has recorded 31 cases of cerebral sinus vein thrombosis (CSVT), nine of which resulted in death, after people were given the Vaxzevria injection. CSVT is a rare form of blood clot that forms in the brain.
Of the 31 cases of CSVT, all except two involved women between the ages of 20 and 63. Before the new guidelines were issued in Berlin, a district in North Rhine-Westphalia state suspended shots for women under 55 after two women suffered from blood clots.
Nearly 2.7 million first doses of Vaxzevria have been administered in Germany. According to official figures, women under the age of 70 make up two-thirds of those vaccinated with the AstraZeneca drug. It’s believed that more women than men have received the shot because nurses were among the first group in Germany to take the jab.
AstraZeneca has been scrambling to reassure governments that its product is safe after more than a dozen countries temporarily halted their rollout of the vaccine following similar reports of blood clots. Canada is the latest country to issue an advisory about the drug, instructing that the vaccine should not be administered to people younger than 55.
EU health authorities have insisted that the vaccine is safe and that the medical episodes cannot be linked to the jab.